Abstracts tagged "Malignancy and systemic lupus erythematosus (SLE)"

Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Basile Tessier-Cloutier¹, David Twa², Eva Baecklund³, Randy Gascoyne⁴, Nathalie A. Johnson⁵, Carin Backlin³, Diane L. Kamen⁶, Ann E. Clarke⁷, Rosalind Ramsey-Goldman⁸, Jennifer LF Lee⁹, Pedro Farinha⁴ and Sasha Bernatsky¹⁰, ¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, ⁵Department of Oncology, McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸FSM, Northwestern University, Chicago, IL, ⁹Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…
Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Sasha Bernatsky¹, Murray Urowitz², John G Hanly³, Ann E. Clarke⁴, Marvin J. Fritzler⁵, Caroline Gordon⁶, Juanita Romero-Diaz⁷, Graciela S. Alarcón⁸, Sang-Cheol Bae⁹, Michelle Petri¹⁰, Joan T. Merrill¹¹, Daniel J. Wallace¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, David A. Isenberg¹⁵, Anisur Rahman¹⁶, Susan Manzi¹⁷, Ola Nived¹⁸, Gunnar K. Sturfelt¹⁹, Christine A. Peschken²⁰, Jorge Sanchez-Guerrero²¹, Guillermo Ruiz-Irastorza²², Cynthia Aranow²³, Ronald F van Vollenhoven²⁴, Asad Zoma²⁵, Kristján Steinsson²⁶, Munther A Khamashta²⁷, Ellen M. Ginzler²⁸, Anca Askanase²⁹, Kenneth C. Kalunian³⁰, Mary Anne Dooley³¹, S. Sam Lim³², Diane L. Kamen³³, Søren Jacobsen³⁴, Manuel Ramos-Casals³⁵, Murat Inanc³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹⁰Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁸Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁰RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²²Biocruces Health Research Institute, Barakaldo, Spain, ²³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²⁴AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁵University of Glasgow, Glaskow, United Kingdom, ²⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁷Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁸Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹UNC Kidney Centre, Chapel Hill, NC, ³²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³⁵Hospital Clinic, Barcelona, Spain, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…
Abstract Number: 2990 • 2016 ACR/ARHP Annual Meeting
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Sasha Bernatsky¹, Murray Urowitz², John Hanly³, Ann E. Clarke⁴, Caroline Gordon⁵, Juanita Romero-Diaz⁶, Graciela S. Alarcon⁷, Sang-Cheol Bae⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Daniel J Wallace¹¹, Paul R. Fortin¹², Dafna D. Gladman¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Ola Nived¹⁷, Gunnar K. Sturfelt¹⁸, Christine Peschken¹⁹, Jorge Sánchez-Guerrero²⁰, Guillermo Ruiz-Irastorza²¹, Cynthia Aranow²², Ronald F. van Vollenhoven²³, Asad Zoma²⁴, Kristján Steinsson²⁵, M Khamashta²⁶, Ellen M. Ginzler²⁷, Anca Askanase²⁸, Kenneth C. Kalunian²⁹, Mary Anne Dooley³⁰, S. Sam Lim³¹, Diane L. Kamen³², Søren Jacobsen³³, Manuel Ramos-Casals³⁴, Murat Inanc³⁵, Jeremy Labrecque³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of, ⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Université Laval, CHU de Québec, Québec, QC, Canada, ¹³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁶Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁷Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁸Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ¹⁹Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ²⁰Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ²¹Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ²⁴Hairmyres Hospital, Scotland, United Kingdom, ²⁵Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁶Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁷Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ²⁸NYU, Seligman Centre for Advanced Therapeutics, New York, NY, ²⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁰Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ³¹Medicine, Emory University School of Medicine, Atlanta, GA, ³²Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³³Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Internal Medicine, Istanbul University, Istanbul, Turkey, ³⁶Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ³⁷Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: Published studies of cancer risk in SLE to date have never focussed solely on clinically confirmed, incident patients. Prior studies thus may not reflect the cancer…
Abstract Number: 719 • 2015 ACR/ARHP Annual Meeting
Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
Basile Tessier Cloutier¹, Pedro Farinha², Sasha Bernatsky³, Eva Baecklund⁴, Ann E. Clarke⁵, Rosalind Ramsey-Goldman⁶, Randy Gascoyne⁷ and SLICC Investigators, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Pathology, BC Cancer Agency, Vancouver, BC, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden, ⁵Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ⁶Fsm # M300, SLICC, Chicago, IL, ⁷Pathology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Background/Purpose: SLE has been consistently associated with an increased incidence of malignant lymphoma, especially the DLBCL subtype. Since the last WHO classification of 2008 DLBCL…
Abstract Number: 763 • 2015 ACR/ARHP Annual Meeting
Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma
Sasha Bernatsky^1,2, John Spinelli³, Patrick M. Gaffney⁴, Karin E Smedby⁵, Rosalind Ramsey-Goldman⁶, Sophia Wang⁷ and Ann E. Clarke⁸, ¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ³School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Fsm # M300, Northwestern University, Chicago, IL, ⁷Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁸Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: The determinants behind the increased risk of non-Hodgkin Lymphoma (NHL) in systemic lupus (SLE) are unclear. The most common type of NHL in SLE…
Abstract Number: 2791 • 2014 ACR/ARHP Annual Meeting
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2570 • 2012 ACR/ARHP Annual Meeting
Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment
Sasha Bernatsky¹, Ann E. Clarke², Karen H. Costenbader³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Paul R. Fortin⁶, Michelle Petri⁷, Susan Manzi⁸, D.A. Isenberg⁹, Anisur Rahman¹⁰, Daniel Wallace¹¹, Caroline Gordon¹², Christine Peschken¹³, Mary Anne Dooley¹⁴, E.M. Ginzler¹⁵, Cynthia Aranow¹⁶, Steven M. Edworthy¹⁷, Ola Nived¹⁸, Søren Jacobsen¹⁹, Guillermo Ruiz-Irastorza²⁰, Edward H. Yelin²¹, Susan G. Barr²², Irene Blanco²³, Candace H. Feldman²⁴ and R. Ramsey-Goldman²⁵, ¹Clinical Epidemiology, Systemic Lupus International Collaborating Clinics, Montreal, QC, Canada, ²Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto,, Toronto, ON, Canada, ⁵Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶University of Laval, Quebec, QC, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁰Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹¹Cedars-Sinai/UCLA, Los Angeles, CA, ¹²School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁵Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁶Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷The University of Calgary, Calgary, AB, Canada, ¹⁸Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ¹⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ²¹Medicine, UC San Francisco, San Francisco, CA, ²²University of Calgary, University of Calgary, Calgary, AB, Canada, ²³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁵Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: In systemic lupus (SLE), concern exists about immunosuppressive drugs and lymphoma risk, Yet, the relative influence of disease activity vs treatment, is unknown. Our objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].